GB201005262D0 - Granulysin and derived peptides: use as novel anthelmintic molecules - Google Patents

Granulysin and derived peptides: use as novel anthelmintic molecules

Info

Publication number
GB201005262D0
GB201005262D0 GBGB1005262.9A GB201005262A GB201005262D0 GB 201005262 D0 GB201005262 D0 GB 201005262D0 GB 201005262 A GB201005262 A GB 201005262A GB 201005262 D0 GB201005262 D0 GB 201005262D0
Authority
GB
United Kingdom
Prior art keywords
granulysin
molecules
derived peptides
novel anthelmintic
anthelmintic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1005262.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRAIG NICOLA M
Original Assignee
CRAIG NICOLA M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CRAIG NICOLA M filed Critical CRAIG NICOLA M
Priority to GBGB1005262.9A priority Critical patent/GB201005262D0/en
Priority to GB1006938A priority patent/GB2479212A/en
Publication of GB201005262D0 publication Critical patent/GB201005262D0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
    • G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are uses of granulysin, its variants, isoforms and homologues, or peptides derived by alteration of granulysin, its variants, isoforms or its homologues, in methods of diagnosing, preventing or treating helminth infections.
GBGB1005262.9A 2010-03-29 2010-03-29 Granulysin and derived peptides: use as novel anthelmintic molecules Ceased GB201005262D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1005262.9A GB201005262D0 (en) 2010-03-29 2010-03-29 Granulysin and derived peptides: use as novel anthelmintic molecules
GB1006938A GB2479212A (en) 2010-03-29 2010-04-26 Granulysin for the treatment of helminth infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1005262.9A GB201005262D0 (en) 2010-03-29 2010-03-29 Granulysin and derived peptides: use as novel anthelmintic molecules

Publications (1)

Publication Number Publication Date
GB201005262D0 true GB201005262D0 (en) 2010-05-12

Family

ID=42228530

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1005262.9A Ceased GB201005262D0 (en) 2010-03-29 2010-03-29 Granulysin and derived peptides: use as novel anthelmintic molecules
GB1006938A Withdrawn GB2479212A (en) 2010-03-29 2010-04-26 Granulysin for the treatment of helminth infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1006938A Withdrawn GB2479212A (en) 2010-03-29 2010-04-26 Granulysin for the treatment of helminth infections

Country Status (1)

Country Link
GB (2) GB201005262D0 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288509B2 (en) * 2002-02-22 2012-10-16 National Hospital Organization Kinki-chuo Chest Medical center Therapeutic agent for infections, and treatment method using the same
US8357365B2 (en) * 2005-02-14 2013-01-22 The Regents Of The University Of California Granulysin peptides and methods of use thereof
US7745390B2 (en) * 2005-05-23 2010-06-29 The Board Of Trustees Of The Leland Stanford Junior University Antimicrobial peptides

Also Published As

Publication number Publication date
GB2479212A (en) 2011-10-05
GB201006938D0 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
EA201291031A1 (en) METHOD OF TREATING OBESITY WITH THE USE OF ANTIOXIDANT INFLAMMATION MODULATORS
MX2016002571A (en) Transduction buffer.
EA201270722A1 (en) RIFAXIMINE FORMS AND THEIR APPLICATION
EA201101521A1 (en) METHODS OF TREATMENT OF ONCOLOGICAL DISEASES, USING EPIMETABOLIC SWITCHES, MULTIPLE-DIFFERENT INTRACELLULAR MOLECULES OR IMPACT FACTORS
TN2012000366A1 (en) Anticoagulant antidotes
MX345762B (en) Anti-infective compounds.
MA32161B1 (en) Rifaximin forms and uses thereof
EA201791850A1 (en) Boron-containing small molecules
MY169328A (en) Compositions for the treatment of dry eye
MX359854B (en) Anti-cxcr3 antibodies.
MX349886B (en) Anti-pseudomonas psl binding molecules and uses thereof.
TW201611843A (en) Methods of treatment with arginine deiminase
WO2014076321A8 (en) Novel specific-binding polypeptides and uses thereof
EA201201623A1 (en) TREATMENT OF DIABETES TYPE 2
PH12014502680A1 (en) Polysaccharide compositions and methods of use
EA201590503A1 (en) ALPHA-1-Microglobulin for use in the treatment of diseases associated with mitochondria
MX359181B (en) Collagen hydrolysate and use thereof.
TN2013000388A1 (en) Anticoagulant antidotes
MX367393B (en) ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SKIN and NAILS.
IN2014DN08385A (en)
IN2014KN02914A (en)
ATE532814T1 (en) NEW AMMONIUM-POLYURETHANE AND/OR POLYCARBONATE COMPOUNDS
MX358132B (en) Thrombin solution and methods of use thereof.
EP2597949A4 (en) Sub-micron compositions
EA201590782A1 (en) ОКСИРАНОВЫЕ АМИНЫ

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)